Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 1Active not recruiting 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Plasma cell 1Myeloid 1Lymphoid 1

Conditions

Prostatic Neoplasms 4Lymphoma, Non-Hodgkin 3Lymphoma 3Uterine Cervical Neoplasms 2Urinary Bladder Neoplasms 2Stomach Neoplasms 2Rectal Neoplasms 2Lymphoma, B-Cell 2Leukemia 2Carcinoma in Situ 2Burkitt Lymphoma 2Vulvar Neoplasms 1Vulvar Diseases 1Uterine Cervical Dysplasia 1Triple Negative Breast Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Philadelphia Chromosome 1Papillomavirus Infections 1Pancreatic Neoplasms 1Oropharyngeal Neoplasms 1Neoplasms 1Neoplasm, Residual 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Multiple Myeloma 1Mesothelioma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Anaplastic 1

Interventions

Cytarabine 48Cyclophosphamide 41Etoposide 34fludarabine phosphate 26Filgrastim 26Peripheral Blood Stem Cell Transplantation 25Radiotherapy 24Daunorubicin 24Vincristine 20Methotrexate 20Busulfan 18Mitoxantrone 15Idarubicin 15Doxorubicin 13Dexamethasone 13Rituximab 12Asparaginase 12Prednisone 11Mercaptopurine 11Cyclosporine 11Thioguanine 9Leucovorin 9Ifosfamide 9Antilymphocyte Serum 9laromustine 8Prednisolone 8fludarabine 7Methylprednisolone 7Interferon-alpha 7aldesleukin 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NIH × Leukemia × Magnetic Resonance Imaging × Clear all
NCT02356159 2025-09-30

Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
34 enrolled 18 charts
LymphoidMyeloidOther hematologic neoplasmPlasma cell

Hodgkin Disease, Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes

NCT00923013 2025-08-08

Cladribine With Simultaneous or Delayed Rituximab to Treat Hairy Cell Leukemia

National Institutes of Health Clinical Center (CC)

Phase 2 Active not recruiting
175 enrolled 16 charts
Other hematologic neoplasm

Leukemia, Leukemia, Hairy Cell, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡